Halozyme Therapeutics (HALO) Tops Q2 EPS by 6c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $100.67 -1.1%
Financial Fact:
Cost of product sales: 9.13M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Cost of product sales: 9.13M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q2 EPS of ($0.16), $0.06 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $35.2 million versus the consensus estimate of $30.09 million.
GUIDANCE:
Halozyme Therapeutics sees FY2018 revenue of $125-135 million, versus the consensus of $128 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- LogicBio Therapeutics (LOGC) Misses Q2 EPS by 10c
- Lument Finance Trust (LFT) Misses Q2 EPS by 17c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
